drugset / Trial / NCT02301104
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of hepatic impairment.
Timeline
- Start
- 2015-01
- Primary completion
- 2016-06
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TAS-102 | Small molecule | 35 mg/m2 | Oral |